Header Logo

Connection

HESHAM MOHAMED to Patient Reported Outcome Measures

Back to Details
This is a "connection" page, showing publications HESHAM MOHAMED has written about Patient Reported Outcome Measures.
HESHAM MOHAMED
Connection Strength
0.034
Patient Reported Outcome Measures
  1. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018 Aug; 97(8):1357-1367.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.